Quantification method for timolol from in vivo samples for the development of a new glaucoma drug depot
Glaucoma is the second most common cause of blindness.An increased intraocular pressure is the only treatable symptom of glaucoma.Because patients often exhibit a poor therapy adherence, a drug depot consisting of ELA-NCO and hyaluronic acid with timolol was developed to ensure sustained drug release.This drug depot is formed by in situ polymerisat